GlassScriptPhysician profile
Daniel Hector Nelson
NPI 1912298167
$6,023.05
in general payments reported to CMS, 2019-2025
27 companies · $1,464 in 2025
The $1,464 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $436 · 2021: $725 · 2022: $526 · 2023: $1,082 · 2024: $1,101 · 2025: $1,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,646.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,481.99 | 2019-2025 | Clareon, Rocklatan, Hydrus Microstent |
| Glaukos Corporation | $790.49 | 2020-2025 | Photrexa Viscous and Photrexa, Photrexa Cross-Linking Kit, Kxl System (Not Refurbished) |
| Amgen INC. | $358.55 | 2024 | Tepezza |
| Dompe US, INC. | $305.40 | 2019-2025 | Oxervate |
| Biotissue Holdings INC. | $299.73 | 2022-2025 | |
| Abbvie INC. | $187.62 | 2024-2025 | |
| Abbott Laboratories | $179.99 | 2021-2023 | Merlin@Home |
| Oyster Point Pharma, INC. | $141.86 | 2022-2025 | Tyrvaya, Ryzumvi |
| E.R. Squibb & Sons, L.L.C. | $141.83 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $129.98 | 2024-2025 | Xdemvy |
| Rxsight INC | $121.25 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Kala Pharmaceuticals, INC. | $119.02 | 2020-2022 | |
| Lantheus Medical Imaging, INC. | $113.49 | 2021 | |
| Horizon Therapeutics Plc | $75.08 | 2022-2023 | Tepezza |
| Angiodynamics, INC. | $69.38 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $66.96 | 2020-2023 | Flarex |
| Novartis Pharmaceuticals Corporation | $66.46 | 2019-2022 | |
| Biosense Webster, INC. | $59.57 | 2025 | Carto 3 |
| Aerie Pharmaceuticals, INC. | $59.17 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $46.83 | 2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $41.56 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $39.07 | 2024-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| Allergan, INC. | $36.89 | 2019-2020 | |
| Boston Scientific Corporation | $33.34 | 2023 | S-Icd System Magnet |
| Harrow Eye, LLC | $22.81 | 2025 | Vevye |
| Shire North American Group INC | $21.10 | 2019 | |
| Ocular Therapeutix, INC. | $13.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.